Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial

September 15, 2016 5:52 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Aerie Pharma (NASDAQ: AERI) is recently up $12.17 to $33.30 in the premarket after reporting 'successful' efficacy results of Phase 3 Roclatan trial. September call option implied volatility is at 190, October is at 200; compared to its 52-week range of 63 to 274.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment